Savara Reports $235.7M Cash Reserves, Optimistic Outlook for 2026
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Mar 13 2026
0mins
Should l Buy SVRA?
As of December 31, 2025, the company had cash, cash equivalents and short-term investments of $235.7M. "Over the last year, we significantly advanced the MOLBREEVI development program," said Matt Pauls, chair and CEO, Savara. "With the filing of the BLA, an assigned PDUFA date of August 22nd, and submission of the MAAs we have strong momentum. U.S. commercial planning is underway, most notably with the onboarding of a market development team that will be complete in the second quarter. With approximately $236 million in cash and access to up to an additional $150 million in non-dilutive capital through debt and royalty structures upon MOLBREEVI approval, we can fund global commercial launch activities. Strong financial flexibility combined with meaningful near-term catalysts means we enter 2026 in a position of strength and confidence."
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy SVRA?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on SVRA
Wall Street analysts forecast SVRA stock price to rise
6 Analyst Rating
6 Buy
0 Hold
0 Sell
Strong Buy
Current: 5.050
Low
9.00
Averages
10.17
High
11.00
Current: 5.050
Low
9.00
Averages
10.17
High
11.00
About SVRA
Savara Inc. is a clinical-stage biopharmaceutical company. The Company is focused on rare respiratory diseases. The Company’s lead program, molgramostim inhalation solution (MOLBREEVI or molgramostim), is an inhaled biologic, specifically an inhaled granulocyte-macrophage colony-stimulating factor (GM-CSF) in Phase III development for autoimmune pulmonary alveolar proteinosis (aPAP). MOLBREEVI is an inhaled formulation of recombinant human GM-CSF and is being developed for the treatment of aPAP. MOLBREEVI is administered once daily by inhalation via a high efficiency nebulizer, the eFlow Nebulizer System (PARI Pharma GmbH). Pulmonary alveolar proteinosis (PAP) is a rare lung disease characterized by the accumulation of surfactant in the alveoli (or air sacs) of the lungs. The Company is engaged in the advancement of the MOLBREEVI aPAP program and the Phase III IMPALA-2 clinical trial and outsourcing capital-intensive operations.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
VR Adviser Increases Stake in Savara by Over 1 Million Shares
- Share Increase: VR Adviser increased its position in Savara by 1,059,332 shares during Q4, bringing its total holdings to 13,740,375 shares valued at $82.9 million, reflecting strong confidence in the company.
- Asset Management Proportion: Savara's shares account for 4.1% of VR Adviser's over $2 billion in assets under management, indicating its significance in the firm's portfolio and potential influence on future investment decisions.
- Market Potential: Savara focuses on developing inhaled biologics for rare respiratory diseases, and although it currently lacks approved products, its lead candidate, molgramostim, is in late-stage trials and aims to address significant unmet medical needs, suggesting long-term market potential.
- Investment Risks: While Savara's stock surged 96.4% last year, investors should be aware of the high-risk nature of the biotech industry, as Savara has no revenue-generating products, making its future stock performance heavily reliant on regulatory approvals and potential revenue from its lead drug candidate.
See More
VR Adviser Increases Stake in Savara by Over 1 Million Shares
- Share Increase: VR Adviser increased its position in Savara by 1,059,332 shares during Q4, bringing its total holdings to 13,740,375 shares valued at $82.9 million, reflecting confidence in Savara's future performance.
- AUM Proportion: Savara represents 4.1% of VR Adviser's total assets under management, highlighting its strategic significance among the firm's 27 positions and indicating a strong belief in the company's potential.
- Market Performance: Savara's stock gained 96.4% in 2022, leading investors to maintain an optimistic outlook for continued growth, particularly with expectations for 2025's performance.
- Risk Advisory: While Savara shows promise in the biotech sector, the lack of approved products and current revenue generation necessitates caution from investors due to the inherent high-risk nature of the investment.
See More
Savara Reports Q4 and FY 2025 Financial Results
- Financial Overview: Savara reported a GAAP EPS of -$0.13 for Q4 2025, indicating ongoing profitability challenges, although the company maintains $235.7 million in cash and short-term investments, ensuring operational funding for future endeavors.
- R&D Expense Increase: R&D expenses rose to $81.4 million in FY 2025 from $78.0 million in FY 2024, a 4.3% increase primarily driven by costs associated with the MOLBREEVI program, including $5.7 million for regulatory affairs and quality assurance, reflecting the company's commitment to drug development.
- Surge in Administrative Costs: Savara's general and administrative expenses surged by $17.0 million to $42.1 million in FY 2025, a 68% increase, which could negatively impact the company's overall financial health, especially with a net loss of $118.8 million reported.
- Annual Net Loss: The company reported a net loss of $118.8 million for FY 2025, translating to a loss of $0.53 per share, compared to a net loss of $95.9 million and $0.48 per share in FY 2024, highlighting increased pressure on cost control and revenue enhancement efforts.
See More
Savara Achieves Regulatory Milestones for MOLBREEVI in Autoimmune PAP
- Regulatory Progress: Savara has submitted a Biologics License Application (BLA) for MOLBREEVI to the FDA, receiving Priority Review with a PDUFA date set for August 22, 2026, indicating strong momentum in the rare respiratory disease sector.
- Strong Financial Position: As of December 31, 2025, Savara reported approximately $236 million in cash and short-term investments, with access to an additional $150 million in non-dilutive capital upon FDA approval, ensuring robust funding for global launch activities.
- Increased R&D Spending: The company reported $20.9 million in R&D expenses for Q4 2025, reflecting a strategic focus on the MOLBREEVI program, despite a slight decrease from 2024, with total annual R&D expenses rising by 4.3% year-over-year.
- Market Development Team Formation: Savara is advancing U.S. commercial planning, with a market development team expected to be fully onboarded by Q2, which will lay the groundwork for MOLBREEVI's market introduction and enhance the company's competitive positioning.
See More
SAVARA ANNOUNCES 2025 FOURTH QUARTER AND YEAR-END FINANCIAL RESULTS ALONG WITH BUSINESS UPDATE
Financial Results Overview: Savara has released its financial results for the fourth quarter and year-end 2025, detailing its performance and financial health.
Business Update: The report provides insights into the company's business developments and strategic direction moving forward.
See More
Savara Receives FDA Day 74 Letter, MOLBREEVI Progressing Smoothly
- FDA Review Progress: Savara has received a Day 74 Letter from the FDA indicating that no Advisory Committee meeting is planned for the MOLBREEVI Biologics License Application (BLA), with ongoing review expected to conclude by the PDUFA target action date of August 22, 2026, laying a solid foundation for market entry.
- EMA Application Submission: The company has submitted the Marketing Authorization Application (MAA) for MOLBREEVI to the European Medicines Agency (EMA) and is on track to submit to the U.K.'s Medicines and Healthcare Products Regulatory Agency (MHRA) by the end of Q1 2026, further advancing its European market strategy.
- Therapeutic Potential: MOLBREEVI is positioned as a first-in-class treatment for autoimmune pulmonary alveolar proteinosis (PAP), a rare disease with no approved therapies in the U.S. and Europe, which could fill a significant market gap and meet urgent patient needs if approved.
- Regulatory Recognition: MOLBREEVI has received Fast Track and Breakthrough Therapy Designations from the FDA, as well as Orphan Drug Designation from both the FDA and EMA, highlighting regulatory confidence in its potential efficacy, which may expedite its market launch and enhance competitive positioning.
See More
VR Adviser Increases Stake in Savara by Over 1 Million Shares
- Share Increase: VR Adviser increased its position in Savara by 1,059,332 shares during Q4, bringing its total holdings to 13,740,375 shares valued at $82.9 million, reflecting strong confidence in the company.
- Asset Management Proportion: Savara's shares account for 4.1% of VR Adviser's over $2 billion in assets under management, indicating its significance in the firm's portfolio and potential influence on future investment decisions.
- Market Potential: Savara focuses on developing inhaled biologics for rare respiratory diseases, and although it currently lacks approved products, its lead candidate, molgramostim, is in late-stage trials and aims to address significant unmet medical needs, suggesting long-term market potential.
- Investment Risks: While Savara's stock surged 96.4% last year, investors should be aware of the high-risk nature of the biotech industry, as Savara has no revenue-generating products, making its future stock performance heavily reliant on regulatory approvals and potential revenue from its lead drug candidate.
See More
VR Adviser Increases Stake in Savara by Over 1 Million Shares
- Share Increase: VR Adviser increased its position in Savara by 1,059,332 shares during Q4, bringing its total holdings to 13,740,375 shares valued at $82.9 million, reflecting confidence in Savara's future performance.
- AUM Proportion: Savara represents 4.1% of VR Adviser's total assets under management, highlighting its strategic significance among the firm's 27 positions and indicating a strong belief in the company's potential.
- Market Performance: Savara's stock gained 96.4% in 2022, leading investors to maintain an optimistic outlook for continued growth, particularly with expectations for 2025's performance.
- Risk Advisory: While Savara shows promise in the biotech sector, the lack of approved products and current revenue generation necessitates caution from investors due to the inherent high-risk nature of the investment.
See More
Savara Reports Q4 and FY 2025 Financial Results
- Financial Overview: Savara reported a GAAP EPS of -$0.13 for Q4 2025, indicating ongoing profitability challenges, although the company maintains $235.7 million in cash and short-term investments, ensuring operational funding for future endeavors.
- R&D Expense Increase: R&D expenses rose to $81.4 million in FY 2025 from $78.0 million in FY 2024, a 4.3% increase primarily driven by costs associated with the MOLBREEVI program, including $5.7 million for regulatory affairs and quality assurance, reflecting the company's commitment to drug development.
- Surge in Administrative Costs: Savara's general and administrative expenses surged by $17.0 million to $42.1 million in FY 2025, a 68% increase, which could negatively impact the company's overall financial health, especially with a net loss of $118.8 million reported.
- Annual Net Loss: The company reported a net loss of $118.8 million for FY 2025, translating to a loss of $0.53 per share, compared to a net loss of $95.9 million and $0.48 per share in FY 2024, highlighting increased pressure on cost control and revenue enhancement efforts.
See More
Savara Achieves Regulatory Milestones for MOLBREEVI in Autoimmune PAP
- Regulatory Progress: Savara has submitted a Biologics License Application (BLA) for MOLBREEVI to the FDA, receiving Priority Review with a PDUFA date set for August 22, 2026, indicating strong momentum in the rare respiratory disease sector.
- Strong Financial Position: As of December 31, 2025, Savara reported approximately $236 million in cash and short-term investments, with access to an additional $150 million in non-dilutive capital upon FDA approval, ensuring robust funding for global launch activities.
- Increased R&D Spending: The company reported $20.9 million in R&D expenses for Q4 2025, reflecting a strategic focus on the MOLBREEVI program, despite a slight decrease from 2024, with total annual R&D expenses rising by 4.3% year-over-year.
- Market Development Team Formation: Savara is advancing U.S. commercial planning, with a market development team expected to be fully onboarded by Q2, which will lay the groundwork for MOLBREEVI's market introduction and enhance the company's competitive positioning.
See More
SAVARA ANNOUNCES 2025 FOURTH QUARTER AND YEAR-END FINANCIAL RESULTS ALONG WITH BUSINESS UPDATE
Financial Results Overview: Savara has released its financial results for the fourth quarter and year-end 2025, detailing its performance and financial health.
Business Update: The report provides insights into the company's business developments and strategic direction moving forward.
See More
Savara Receives FDA Day 74 Letter, MOLBREEVI Progressing Smoothly
- FDA Review Progress: Savara has received a Day 74 Letter from the FDA indicating that no Advisory Committee meeting is planned for the MOLBREEVI Biologics License Application (BLA), with ongoing review expected to conclude by the PDUFA target action date of August 22, 2026, laying a solid foundation for market entry.
- EMA Application Submission: The company has submitted the Marketing Authorization Application (MAA) for MOLBREEVI to the European Medicines Agency (EMA) and is on track to submit to the U.K.'s Medicines and Healthcare Products Regulatory Agency (MHRA) by the end of Q1 2026, further advancing its European market strategy.
- Therapeutic Potential: MOLBREEVI is positioned as a first-in-class treatment for autoimmune pulmonary alveolar proteinosis (PAP), a rare disease with no approved therapies in the U.S. and Europe, which could fill a significant market gap and meet urgent patient needs if approved.
- Regulatory Recognition: MOLBREEVI has received Fast Track and Breakthrough Therapy Designations from the FDA, as well as Orphan Drug Designation from both the FDA and EMA, highlighting regulatory confidence in its potential efficacy, which may expedite its market launch and enhance competitive positioning.
See More
